An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

803

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
DyslipidemiaObesity
Interventions
DRUG

Rimonabant (SR141716)

DRUG

Placebo

Trial Locations (14)

08807

Sanofi-aventis Administrative Office, Bridgewater

Unknown

Sanofi-aventis Administrative Office, Macquarie Park

Sanofi-aventis Administrative Office, São Paulo

Sanofi-aventis Administrative Office, Laval

Sanofi-aventis Administrative Office, Hørsholm

Sanofi-aventis Administrative Office, Causeway Bay

Sanofi-aventis Administrative Office, Milan

Sanofi-aventis Administrative Office, Kuala Lumpur

Sanofi-aventis Administrative Office, México

Sanofi-aventis Administrative Office, Singapore

Sanofi-aventis Administrative Office, Midrand

Sanofi-aventis Administrative Office, Seoul

Sanofi-aventis Administrative Office, Bromma

Sanofi-aventis Administrative Office, Taipei

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY